Cargando…

Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an age-related disease with no cure. Mesenchymal stem cell (MSC)-based therapy has emerged as a novel strategy for IPF treatment. Nevertheless, MSCs derived from patients with IPF (IPF-MSCs) become senescent, thereby reducing their beneficial effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Linli, Han, Qian, Hong, Yimei, Li, Weifeng, Gong, Gencheng, Cui, Jiangyu, Mao, Mengmeng, Liang, Xiaoting, Hu, Bei, Li, Xin, Luo, Qun, Zhang, Yuelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905557/
https://www.ncbi.nlm.nih.gov/pubmed/33632305
http://dx.doi.org/10.1186/s13287-021-02215-x
_version_ 1783655130086768640
author Shi, Linli
Han, Qian
Hong, Yimei
Li, Weifeng
Gong, Gencheng
Cui, Jiangyu
Mao, Mengmeng
Liang, Xiaoting
Hu, Bei
Li, Xin
Luo, Qun
Zhang, Yuelin
author_facet Shi, Linli
Han, Qian
Hong, Yimei
Li, Weifeng
Gong, Gencheng
Cui, Jiangyu
Mao, Mengmeng
Liang, Xiaoting
Hu, Bei
Li, Xin
Luo, Qun
Zhang, Yuelin
author_sort Shi, Linli
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an age-related disease with no cure. Mesenchymal stem cell (MSC)-based therapy has emerged as a novel strategy for IPF treatment. Nevertheless, MSCs derived from patients with IPF (IPF-MSCs) become senescent, thereby reducing their beneficial effects in IPF. MicroRNAs (miRNAs) mediate the senescence of MSCs, but the underlying mechanisms are not fully understood. We investigated the mechanisms by which miR-199a-5p regulates IPF-MSC senescence and whether its inhibition could rejuvenate IPF-MSCs and enhance their therapeutic efficacy. METHODS: Control-MSCs and IPF-MSCs were isolated from the adipose tissue of age-matched healthy and IPF donors, respectively. Cell senescence was examined by senescence-associated β-galactosidase (SA-β-gal) staining. The level of miR-199a-5p was measured by RT-PCR. Autophagy was determined using a transmission electron microscope (TEM). The therapeutic efficacy of anti-miR-199a-5p-IPF-MSCs was assessed using a mouse model of bleomycin-induced lung fibrosis. RESULTS: Despite similar surface makers, IPF-MSCs exhibited increased cellular senescence and decreased proliferative capacity compared with control-MSCs. The expression of miR-199a-5p was significantly enhanced in the serum of IPF patients and IPF-MSCs compared with that of healthy donors and control-MSCs. The upregulation of miR-199a-5p induced senescence of control-MSCs, whereas the downregulation rescued IPF-MSC senescence. Mechanistically, miR-155-5p suppressed autophagy of MSCs via the AMPK signaling pathway by downregulating the expression of Sirtuin 1(Sirt1), resulting in cellular senescence. Accordingly, miR-155-5p inhibition promoted autophagy and ameliorated IPF-MSC senescence by activating the Sirt1/AMPK signaling pathway. Compared with IPF-MSCs, the transplantation of anti-miR-199a-5p-IPF-MSCs increased the ability to prevent progression of pulmonary fibrosis in bleomycin-treated mice. CONCLUSIONS: Our study shows that miR-199a-5p regulates MSC senescence in patients with IPF by regulating the Sirt1/AMPK signaling pathway and miR-199a-5p is a novel target to rejuvenate IPF-MSCs and enhance their beneficial effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-021-02215-x.
format Online
Article
Text
id pubmed-7905557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79055572021-02-25 Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis Shi, Linli Han, Qian Hong, Yimei Li, Weifeng Gong, Gencheng Cui, Jiangyu Mao, Mengmeng Liang, Xiaoting Hu, Bei Li, Xin Luo, Qun Zhang, Yuelin Stem Cell Res Ther Research BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an age-related disease with no cure. Mesenchymal stem cell (MSC)-based therapy has emerged as a novel strategy for IPF treatment. Nevertheless, MSCs derived from patients with IPF (IPF-MSCs) become senescent, thereby reducing their beneficial effects in IPF. MicroRNAs (miRNAs) mediate the senescence of MSCs, but the underlying mechanisms are not fully understood. We investigated the mechanisms by which miR-199a-5p regulates IPF-MSC senescence and whether its inhibition could rejuvenate IPF-MSCs and enhance their therapeutic efficacy. METHODS: Control-MSCs and IPF-MSCs were isolated from the adipose tissue of age-matched healthy and IPF donors, respectively. Cell senescence was examined by senescence-associated β-galactosidase (SA-β-gal) staining. The level of miR-199a-5p was measured by RT-PCR. Autophagy was determined using a transmission electron microscope (TEM). The therapeutic efficacy of anti-miR-199a-5p-IPF-MSCs was assessed using a mouse model of bleomycin-induced lung fibrosis. RESULTS: Despite similar surface makers, IPF-MSCs exhibited increased cellular senescence and decreased proliferative capacity compared with control-MSCs. The expression of miR-199a-5p was significantly enhanced in the serum of IPF patients and IPF-MSCs compared with that of healthy donors and control-MSCs. The upregulation of miR-199a-5p induced senescence of control-MSCs, whereas the downregulation rescued IPF-MSC senescence. Mechanistically, miR-155-5p suppressed autophagy of MSCs via the AMPK signaling pathway by downregulating the expression of Sirtuin 1(Sirt1), resulting in cellular senescence. Accordingly, miR-155-5p inhibition promoted autophagy and ameliorated IPF-MSC senescence by activating the Sirt1/AMPK signaling pathway. Compared with IPF-MSCs, the transplantation of anti-miR-199a-5p-IPF-MSCs increased the ability to prevent progression of pulmonary fibrosis in bleomycin-treated mice. CONCLUSIONS: Our study shows that miR-199a-5p regulates MSC senescence in patients with IPF by regulating the Sirt1/AMPK signaling pathway and miR-199a-5p is a novel target to rejuvenate IPF-MSCs and enhance their beneficial effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-021-02215-x. BioMed Central 2021-02-25 /pmc/articles/PMC7905557/ /pubmed/33632305 http://dx.doi.org/10.1186/s13287-021-02215-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shi, Linli
Han, Qian
Hong, Yimei
Li, Weifeng
Gong, Gencheng
Cui, Jiangyu
Mao, Mengmeng
Liang, Xiaoting
Hu, Bei
Li, Xin
Luo, Qun
Zhang, Yuelin
Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
title Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
title_full Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
title_fullStr Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
title_full_unstemmed Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
title_short Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
title_sort inhibition of mir-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905557/
https://www.ncbi.nlm.nih.gov/pubmed/33632305
http://dx.doi.org/10.1186/s13287-021-02215-x
work_keys_str_mv AT shilinli inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT hanqian inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT hongyimei inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT liweifeng inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT gonggencheng inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT cuijiangyu inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT maomengmeng inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT liangxiaoting inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT hubei inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT lixin inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT luoqun inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis
AT zhangyuelin inhibitionofmir199a5prejuvenatesagedmesenchymalstemcellsderivedfrompatientswithidiopathicpulmonaryfibrosisandimprovestheirtherapeuticefficacyinexperimentalpulmonaryfibrosis